公开(公告)号：US20240168012A1

公开(公告)日：2024-05-23

申请号：US18283434

申请日：2022-03-21

申请人： Juno Therapeutics, Inc.

发明人： Neil HAIG

IPC分类号： G01N33/50

CPC分类号： G01N33/505 ,  G01N33/5011 ,  G01N2333/70514 ,  G01N2333/70517

摘要： The present disclosure relates to methods of determining potency of a therapeutic cell compositions in connection with cell therapy. The cells of the therapeutic cell composition can express recombinant receptors such as chimeric receptors, e.g., chimeric antigen receptors (CARs) or other transgenic receptors such as T cell receptors (TCRs). The methods provide an assay for identifying the potency, including relative potency, of a therapeutic cell composition.

公开(公告)号：US20240302349A1

公开(公告)日：2024-09-12

申请号：US18674099

申请日：2024-05-24

申请人： Juno Therapeutics, Inc.

发明人： Trevor DO ,  Howard STERN ,  Christina SWANSON

IPC分类号： G01N33/50 ,  A61K35/17 ,  C07K14/705

CPC分类号： G01N33/5017 ,  A61K35/17 ,  C07K14/705 ,  G01N33/5091 ,  G01N2333/70514 ,  G01N2800/52

摘要： Provided are methods and articles of manufacture for use with cell therapy for the treatment of diseases or conditions, e.g., cancer, including for predicting likelihood of the subject responding to a therapy, such as a cell therapy, e.g., a chimeric antigen receptor (CAR) T cell therapy. In some aspects, the predicting is based on detecting certain biomarkers of immune cells associated with and/or that correlate with response following administration of the therapy. The methods generally involve detecting a marker by assaying a biological sample from a subject that is a candidate for treatment, optionally with a cell therapy, to determine if the subject is likely to respond to the therapy. The present disclosure also provides methods for treating a subject having a disease or condition, in some cases involving administration of the cell therapy, based on assessment the biomarker. Also provided herein are reagents and kits for performing the methods.

公开(公告)号：US11944647B2

公开(公告)日：2024-04-02

申请号：US17846868

申请日：2022-06-22

申请人： Juno Therapeutics, Inc.

发明人： Tina Albertson ,  Brian Christin ,  Jacob Randolph Garcia ,  Christopher Glen Ramsborg ,  Claire L. Sutherland ,  Clinton Weber ,  Rachel K. Yost ,  Mark J. Gilbert ,  He Li

IPC分类号： A61K35/17 ,  A61P35/00 ,  C07K14/705 ,  C07K14/73

CPC分类号： A61K35/17 ,  A61P35/00 ,  C07K14/70514 ,  C07K14/70517

摘要： Provided are adoptive cell therapy methods involving the administration of doses of cells for treating disease and conditions, including certain B cell malignancies. The cells generally express recombinant receptors such as chimeric antigen receptors (CARs). In some embodiments, the methods are for treating subjects with non-Hodgkin lymphoma (NHL). In some embodiments, the methods are for treating subjects with relapsed or refractory NHL. Also provided are articles of manufacture and prophylactic treatments in connection with adoptive therapy methods.

公开(公告)号：US20240053250A1

公开(公告)日：2024-02-15

申请号：US18267744

申请日：2021-12-15

申请人： Juno Therapeutics, Inc.

发明人： Rebecca BRUNETTE ,  Ryan P. LARSON ,  Kevin HAWKINS

IPC分类号： G01N15/14 ,  G01N15/10 ,  G01N21/64

CPC分类号： G01N15/1427 ,  G01N15/1012 ,  G01N21/6486 ,  G01N2015/1402 ,  G01N2015/1488 ,  G01N2015/1018

摘要： Provided are methods for flow cytometry analysis, including the setting and use of static gating thresholds separating positive fluorescence from negative fluorescence for each fluorescence channel in the assay.

公开(公告)号：US11821027B2

公开(公告)日：2023-11-21

申请号：US16476856

申请日：2018-01-10

申请人： Juno Therapeutics, Inc.

发明人： Mark L. Bonyhadi ,  David G. Kugler ,  Timothy G. Johnstone ,  Ronald James Hause, Jr. ,  Lucas J. Thompson ,  Ryan P. Larson

IPC分类号： C12Q1/6827 ,  G16B30/10 ,  C12Q1/6806 ,  C12Q1/6869 ,  C12Q1/6886 ,  G16B20/20 ,  G16B40/10 ,  G16B20/10

CPC分类号： C12Q1/6827 ,  C12Q1/6806 ,  C12Q1/6869 ,  C12Q1/6886 ,  G16B20/10 ,  G16B20/20 ,  G16B30/10 ,  G16B40/10 ,  C12Q2600/142 ,  C12Q2600/154 ,  C12Q2600/156

摘要： Provided herein are methods of identifying genomic region(s) predictive of an outcome of treatment with a cell therapy and/or of a phenotype of function of the cells. In some embodiments, the methods include epigenetic and/or epigenomic analyses of the cells in connection with methods for preparing engineered cells for cell therapy and/or predicting response to a cell therapy, e.g., engineered cells for cell therapy. In some embodiments, the methods include steps to assess, characterize and analyze changes or modifications in an epigenetic property of gene region or regions, such as chromatin accessibility, nucleosome occupancy, histone modification, spatial chromosomal conformation, transcription factor occupancy and/or DNA methylation. In some embodiments, the epigenetic and/or epigenomic analysis includes determining the epigenetic properties of a cell, e.g., an engineered cell for cell therapy.

公开(公告)号：US20230181641A1

公开(公告)日：2023-06-15

申请号：US17924635

申请日：2021-05-12

申请人： Juno Therapeutics, Inc.

发明人： Nathan YEE ,  Ryan LARSON ,  Calvin CHAN ,  Sara COOPER ,  Jeffrey TEOH ,  Daniel COSSETTE ,  Kohana LEUBA

IPC分类号： A61K35/17 ,  C12N5/0783 ,  C07K14/725 ,  C07K14/705 ,  C07K14/715 ,  A61K38/17 ,  A61P35/00

CPC分类号： A61K35/17 ,  C12N5/0636 ,  C07K14/7051 ,  C07K14/70521 ,  C07K14/7151 ,  A61K38/1774 ,  A61P35/00 ,  C12N2500/32 ,  C12N2501/2302 ,  C12N2501/2307 ,  C12N2501/2315 ,  C12N2501/515 ,  C12N2501/51

摘要： Provided herein are methods of producing engineered T cell compositions enriched for CD57 negative and/or CD27 positive T cells, such as from a plurality of donors. In some embodiments, the T cells are engineered with a recombinant receptor, such as a chimeric antigen receptor (CAR). Also provided herein are engineered T cell compositions containing T cells enriched for CD57 negative and/or CD27 positive T cells derived from a plurality of different donors, including compositions in which the T cells are engineered with or express a recombinant receptor (e.g. CAR). Also provided are methods of using the engineered T cell compositions in adoptive therapy, including in connection for cancer immunotherapy, such as for allogeneic therapies or for administration to one or more subjects in which the T cells are not derived from the subject(s) to whom the compositions are administered.

公开(公告)号：US20230178239A1

公开(公告)日：2023-06-08

申请号：US17924652

申请日：2021-05-12

申请人： Juno Therapeutics, Inc.

发明人： Ronald James HAUSE, JR. ,  Yue JIANG

IPC分类号： G16H50/20 ,  A61K35/17 ,  G06N20/20

CPC分类号： G16H50/20 ,  A61K35/17 ,  G06N20/20

摘要： The present disclosure relates to methods for identifying features, such as attributes of subjects, therapeutic cell compositions, and input compositions used to produce therapeutic cell compositions, associated with clinical responses of subjects, e.g., patients, following treatment with the therapeutic cell composition in connection with a cell therapy. The cells of the therapeutic cell composition express recombinant receptors such as chimeric receptors, e.g., chimeric antigen receptors (CARs) or other transgenic receptors such as T cell receptors (TCRs). The methods provide for the identification of features associated with clinical responses. In some embodiments, the methods can be used to determine (e.g., predict) a subject's response to treatment with the therapeutic cell composition.

公开(公告)号：US20230137729A1

公开(公告)日：2023-05-04

申请号：US16758843

申请日：2018-11-05

申请人： EDITAS MEDICINE, INC. ,  JUNO THERAPEUTICS, INC.

发明人： Andreia S. COSTA ,  Jason David FONTENOT ,  Fred HARBINSKI ,  Gordon Grant WELSTEAD ,  Chris WILSON

IPC分类号： C12N15/113 ,  C12N9/22

摘要： CRISPR/CAS-related genome editing systems, compositions and methods for targeting the CBLB locus, as well as cells edited using these systems, compositions and methods are provided.

公开(公告)号：US20230071910A1

公开(公告)日：2023-03-09

申请号：US17794245

申请日：2021-01-22

申请人： Juno Therapeutics, Inc.

发明人： Thalia FARAZI

IPC分类号： A61K35/17 ,  C07K14/725 ,  C07K16/28 ,  C12N5/0783

摘要： Provided herein are methods of administering a dose of T cells for treating subjects with indolent non-Hodgkin3 s lymphoma (NHL), and related methods, compositions, uses and articles of manufacture. The cells express a recombinant receptor such as a chimeric antigen receptor (CAR) for targeting an antigen of the lymphoma, such as CD19. In some embodiments, the methods are for treating grade 1-3 A follicular lymphoma (FL 1-3 A) or marginal zone lymphoma (MZL), including in heavily pretreated or poor-prognosis subjects, such as subjects that have relapsed after treatment with, or are refractory to treatment with, one or more prior therapies.

公开(公告)号：US20230061455A1

公开(公告)日：2023-03-02

申请号：US16758842

申请日：2018-11-01

申请人： EDITAS MEDICINE, INC. ,  JUNO THERAPEUTICS, INC.

发明人： Stephen Michael BURLEIGH ,  Melissa CHIN ,  Fred HARBINSKI ,  Christopher Heath NYE ,  Blythe D. SATHER ,  Queenie VONG ,  Gordon Grant WELSTEAD ,  Chris WILSON

IPC分类号： C12N9/22 ,  C12N15/10 ,  A61P35/00

摘要： CRISPR/CAS-related genome editing systems, compositions and methods for targeting the TGFBR2 locus, as well as cells edited using these systems, compositions and methods are provided.